Overview

A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules

Status:
Completed
Trial end date:
2019-04-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the BA of 30 or 60 milligram (mg) dexlansoprazole capsule manufactured at TOB (Takeda GmbH Plant Oranienburg) to the corresponding 30 or 60 mg dexlansoprazole manufactured at TPC (Takeda Pharmaceutical Company Ltd.).
Phase:
Phase 1
Details
Lead Sponsor:
Takeda
Treatments:
Dexlansoprazole
Lansoprazole